| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5466699 | IPR | Indolyl compounds for treating migraine |
Nov, 2012
(11 years ago) | |
| US5863935 | IPR | Therapeutic heterocyclic compounds |
Nov, 2012
(11 years ago) | |
|
US5466699 (Pediatric) | IPR | Indolyl compounds for treating migraine |
May, 2013
(10 years ago) | |
|
US5863935 (Pediatric) | IPR | Therapeutic heterocyclic compounds |
May, 2013
(10 years ago) | |
Zomig is owned by Ipr.
Zomig contains Zolmitriptan.
Zomig has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Zomig are:
- US5466699
- US5863935
- US5466699*PED
- US5863935*PED
Zomig was authorised for market use on 25 November, 1997.
Zomig is available in tablet;oral dosage forms.
The generics of Zomig are possible to be released after 14 May, 2013.
Drugs and Companies using ZOLMITRIPTAN ingredient
Market Authorisation Date: 25 November, 1997
Treatment: NA
Dosage: TABLET;ORAL
ZOMIG family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5466699 | AMNEAL | Indolyl compounds for treating migraine |
Nov, 2012
(11 years ago) | |
|
US5466699 (Pediatric) | AMNEAL | Indolyl compounds for treating migraine |
May, 2013
(10 years ago) | |
| US7220767 | AMNEAL | Pharmaceutical formulations containing zolmitriptan |
Nov, 2020
(3 years ago) | |
| US6750237 | AMNEAL | Pharmaceutical formulations containing zolmitriptan |
Nov, 2020
(3 years ago) | |
|
US7220767 (Pediatric) | AMNEAL | Pharmaceutical formulations containing zolmitriptan |
May, 2021
(2 years ago) | |
|
US6750237 (Pediatric) | AMNEAL | Pharmaceutical formulations containing zolmitriptan |
May, 2021
(2 years ago) | |
Zomig is owned by Amneal.
Zomig contains Zolmitriptan.
Zomig has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Zomig are:
- US5466699
- US5466699*PED
- US7220767
- US6750237
- US7220767*PED
- US6750237*PED
Zomig was authorised for market use on 16 September, 2013.
Zomig is available in spray;nasal dosage forms.
Zomig can be used as acute treatment of migraine attacks with or without aura in adults.
The generics of Zomig are possible to be released after 28 May, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 12, 2018 |
Drugs and Companies using ZOLMITRIPTAN ingredient
Market Authorisation Date: 16 September, 2013
Treatment: Acute treatment of migraine attacks with or without aura in adults
Dosage: SPRAY;NASAL
ZOMIG family patents